Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Income from Continuing Operations: 2011-2025

Historic Income from Continuing Operations for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to -$14.4 million.

  • Aytu Biopharma's Income from Continuing Operations rose 79.78% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.5 million, marking a year-over-year decrease of 239.91%. This contributed to the annual value of -$14.4 million for FY2025, which is 14.99% down from last year.
  • Per Aytu Biopharma's latest filing, its Income from Continuing Operations stood at -$14.4 million for FY2025, which was down 14.99% from -$12.5 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Income from Continuing Operations ranged from a high of -$12.5 million in FY2024 and a low of -$108.8 million during FY2022.
  • For the 3-year period, Aytu Biopharma's Income from Continuing Operations averaged around -$14.7 million, with its median value being -$14.4 million (2025).
  • In the last 5 years, Aytu Biopharma's Income from Continuing Operations plummeted by 327.93% in 2021 and then spiked by 84.21% in 2023.
  • Over the past 5 years, Aytu Biopharma's Income from Continuing Operations (Yearly) stood at -$58.3 million in 2021, then tumbled by 86.62% to -$108.8 million in 2022, then surged by 84.21% to -$17.2 million in 2023, then climbed by 27.11% to -$12.5 million in 2024, then dropped by 14.99% to -$14.4 million in 2025.